Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters

Journal of Pharmaceutical Sciences
Masahiro YahataYuichi Sugiyama

Abstract

Accurate prediction of target occupancy facilitates central nervous system drug development. In this review, we discuss the predictability of serotonin transporter (SERT) occupancy in human brain estimated from in vitro Ki values for human SERT and plasma concentrations of unbound drug (Cu,plasma), as well as the impact of drug transporters in the blood-brain barrier. First, the geometric means of in vitro Ki values were compared with the means of in vivo Ki values (Ki,u,plasma) which were calculated as Cu,plasma values at 50% occupancy of SERT obtained from previous clinical positron emission tomography/single photon emission computed tomography imaging studies for 6 selective serotonin transporter reuptake inhibitors and 3 serotonin norepinephrine reuptake inhibitors. The in vitro Ki values for 7 drugs were comparable to their in vivo Ki,u,plasma values within 3-fold difference. SERT occupancy was overestimated for 5 drugs (P-glycoprotein substrates) and underestimated for 2 drugs (presumably uptake transporter substrates, although no evidence exists as yet). In conclusion, prediction of human SERT occupancy from in vitro Ki values and Cu,plasma was successful for drugs that are not transporter substrates and will become poss...Continue Reading

References

Jan 1, 1988·Fundamental & Clinical Pharmacology·J P TillementJ Barre
Dec 1, 1996·NeuroImage·A A Lammertsma, S P Hume
Apr 16, 1998·European Journal of Pharmacology·M TatsumiE Richelson
Jun 6, 2000·Advanced Drug Delivery Reviews·A H Schinkel
Aug 15, 2001·Clinical Pharmacology and Therapeutics·R B KimG R Wilkinson
May 8, 2002·British Journal of Clinical Pharmacology·Siegfried DrescherMartin F Fromm
Jun 29, 2002·Journal of the American Society of Nephrology : JASN·Michael SiegsmundHiltrud Brauch
Aug 22, 2002·Clinical Pharmacology and Therapeutics·Yasuo KurataKenji Otsubo
Dec 21, 2002·British Journal of Clinical Pharmacology·Thomas GerloffIvar Roots
Jan 25, 2003·Clinical Pharmacology and Therapeutics·Céline VerstuyftLaurent Becquemont
Mar 26, 2003·Journal of Psychiatric Research·Manfred Uhr, Markus T Grauer
Oct 27, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Angela DoranChenghong Zhang
Feb 8, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fenghua ChenOve Wiborg
Sep 1, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Kjell ErlandssonPeter J Ell
Sep 6, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·B B WekslerP O Couraud
Mar 1, 2006·Psychopharmacology·Akihiro TakanoTetsuya Suhara
May 6, 2006·The Journal of Pharmacology and Experimental Therapeutics·Darlene C DeecherTerrance H Andree
May 17, 2006·The Journal of Pharmacology and Experimental Therapeutics·Ilaria BadagnaniKathleen M Giacomini
Feb 6, 2007·Molecular Pharmaceutics·Tomoji MaedaIkumi Tamai
Jul 24, 2007·Molecular Pharmacology·Junichi EnokizonoYuichi Sugiyama
Oct 5, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Masaki KatoToshihiko Kinoshita
Oct 27, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bo FengSonia M de Morais
Jun 14, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alma Mihaljevic PelesMila Lovric
Jul 22, 2008·Therapeutic Drug Monitoring·Marianne Gex-FabryGilles Bertschy
Sep 20, 2008·The Journal of Pharmacology and Experimental Therapeutics·Subbu ApparsundaramRenee S Martin
Oct 23, 2008·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Georg NikischPierre Baumann
Dec 24, 2008·Pharmacogenomics·Adrián LlerenaEva M Peñas-Lledó
May 15, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Louise KarlssonChristoph Hiemke

❮ Previous
Next ❯

Citations

Nov 30, 2018·Journal of Psychopharmacology·Bettadapura N SrikumarReeba K Vikramadithyan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.